drugset / Trial / NCT07556120
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)
Phase 1
Not yet recruiting
6 enrolled
Shenzhen MagicRNA Biotechnology Co., Ltd
The First Affiliated Hospital of University of Science and Technology of China · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.
Timeline
- Start
- 2026-05-05
- Primary completion
- 2027-05-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HN2301 | Cell therapy | — | — |